Pharma Rep Focus

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

tag allogenic

bluebird bio wins back-to-back landmark FDA approvals for first-in-class gene therapies

Pharmaceutical Technology

SEPTEMBER 30, 2022

Spark Therapeutics’ Luxturna, indicated for inherited retinal disease (IRD), was the first gene therapy to be approved, in 2017, with a price tag of $850,000 for each eye. Prior to bluebird's approvals, there were only two FDA-approved gene therapies for inherited conditions on the market.

FDA

FDA Insurance Patients Marketing

Q&A: A decade on, what’s next for CAR-T therapies?

Pharmaceutical Technology

APRIL 5, 2023

But access to these treatments continues to remain limited due to high price tags and variable availability across regions. This approach remains logistically complex, which builds the desire for allogeneic treatments that can be manufactured from unrelated donors on a larger scale. But there is that significant challenge.

Food and Drug Administration

Food and Drug Administration Engineering Patients Education

bluebird bio wins back-to-back landmark FDA approvals for first-in-class gene therapies

Q&A: A decade on, what’s next for CAR-T therapies?

Stay Connected